Google
LGVN — LONGEVERON LLC (Healthcare >> Biotechnology)
LGVN FAQ
What is LGVN's ROE?
LONGEVERON LLC reports a Return on Equity (ROE) of -139.95%.
What is LGVN's dividend yield?
LONGEVERON LLC offers a dividend yield of 0.00%.
What is LGVN's Deepscope Quality Score?
Deepscope rates LGVN's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LGVN?
Deepscope's AI Timing Score for LGVN is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LGVN belong to?
LONGEVERON LLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.77
Price
-0.00
(-0.32%)
Day Change
|
|
|---|
LGVN, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.77 |
| PBV / Sector |
1.52 / 4.79
GOOD
|
| Earning Per Share | -0.71 |
| PE / Sector |
N/A / 17.89
|
| PEG or PE/Growth / Sector |
N/A / 0.56
|
| Average 1M Daily Value |
0.27 M
GREAT
|
| Average 1W Daily Value |
0.13 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-11 09:55:11 |
| Symbol | LGVN |
| Name | LONGEVERON LLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 30.15 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 24.42 / 8,963.32 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Life Science & Technology Park, Miami, FL, United States, 33136
Phone: 844 470 2550
Website: https://longeveron.com
Sector: Healthcare >> Biotechnology
Description: Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
